| 1. Bisacchi G, Chao S, Bachard C, Daris J, Innaimo S, Jacobs G, Kocy O, Lapointe P, Martel A, Merchant Z, Slusarchyk W, Sundeen J, Young M, Colonno R, Zahler R. (1997) BMS-200475, a novel carbocyclic 2-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro, 7 (2): [10.1016/S0960-894X(96)00594-X] |
| 2. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ.. (2007) Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present., 51 (3): [PMID:17178796] [10.1128/aac.00833-06] |
| 3. Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, Zoulim F.. (2007) In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants., 51 (6): [PMID:17371827] [10.1128/aac.01440-06] |
| 4. Menne S, Asif G, Narayanasamy J, Butler SD, George AL, Hurwitz SJ, Schinazi RF, Chu CK, Cote PJ, Gerin JL, Tennant BC.. (2007) Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection., 51 (9): [PMID:17606676] [10.1128/aac.00325-07] |
| 5. Lin PF, Nowicka-Sans B, Terry B, Zhang S, Wang C, Fan L, Dicker I, Gali V, Higley H, Parkin N, Tenney D, Krystal M, Colonno R.. (2008) Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge., 52 (5): [PMID:18316521] [10.1128/aac.01313-07] |
| 6. Wang YP, Liu F, He HW, Han YX, Peng ZG, Li BW, You XF, Song DQ, Li ZR, Yu LY, Cen S, Hong B, Sun CH, Zhao LX, Kreiswirth B, Perlin D, Shao RG, Jiang JD.. (2010) Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus., 54 (5): [PMID:20176893] [10.1128/aac.01764-09] |
| 7. Lin K, Karwowska S, Lam E, Limoli K, Evans TG, Avila C.. (2010) Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro., 54 (6): [PMID:20308377] [10.1128/aac.01703-09] |
| 8. Suh DJ, Um SH, Herrmann E, Kim JH, Lee YS, Lee HJ, Lee MS, Lee YJ, Bao W, Lopez P, Lee HC, Avila C, Zeuzem S.. (2010) Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B., 54 (3): [PMID:20028815] [10.1128/aac.01163-09] |
| 9. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 10. Unpublished dataset, |
| 11. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 12. Wang J, Singh US, Rawal RK, Sugiyama M, Yoo J, Jha AK, Scroggin M, Huang Z, Murray MG, Govindarajan R, Tanaka Y, Korba B, Chu CK.. (2011) Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants., 21 (21): [PMID:21930377] [10.1016/j.bmcl.2011.08.113] |
| 13. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 14. Rawal RK, Singh US, Chavre SN, Wang J, Sugiyama M, Hung W, Govindarajan R, Korba B, Tanaka Y, Chu CK.. (2013) 2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action., 23 (2): [PMID:23237841] [10.1016/j.bmcl.2012.11.027] |
| 15. PubChem BioAssay data set, |
| 16. Yang Q, Kang J, Zheng L, Wang XJ, Wan N, Wu J, Qiao Y, Niu P, Wang SQ, Peng Y, Wang Q, Yu W, Chang J.. (2015) Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection., 58 (9): [PMID:25905540] [10.1021/jm5012963] |
| 17. WHO Anatomical Therapeutic Chemical Classification, |
| 18. British National Formulary (72nd edition), |
| 19. Ren Q, Liu X, Yan G, Nie B, Zou Z, Li J, Chen Y, Wei Y, Huang J, Luo Z, Gu B, Goldmann S, Zhang J, Zhang Y.. (2018) 3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4., 61 (3): [PMID:29381358] [10.1021/acs.jmedchem.7b01914] |
| 20. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development., 136 (1): [PMID:23956101] [10.1093/toxsci/kft176] |
| 21. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
| 22. Luo M, Groaz E, Andrei G, Snoeck R, Kalkeri R, Ptak RG, Hartman T, Buckheit RW, Schols D, De Jonghe S, Herdewijn P.. (2017) Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs., 60 (14): [PMID:28682067] [10.1021/acs.jmedchem.7b00416] |
| 23. Vandyck K, Rombouts G, Stoops B, Tahri A, Vos A, Verschueren W, Wu Y, Yang J, Hou F, Huang B, Vergauwen K, Dehertogh P, Berke JM, Raboisson P.. (2018) Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)., 61 (14): [PMID:29906396] [10.1021/acs.jmedchem.8b00654] |
| 24. Qiu J, Gong Q, Gao J, Chen W, Zhang Y, Gu X, Tang D.. (2018) Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors., 144 [PMID:29288943] [10.1016/j.ejmech.2017.12.042] |
| 25. Ren Q, Liu X, Luo Z, Li J, Wang C, Goldmann S, Zhang J, Zhang Y.. (2017) Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)., 25 (3): [PMID:28082068] [10.1016/j.bmc.2016.12.017] |
| 26. Sari O, Boucle S, Cox BD, Ozturk T, Russell OO, Bassit L, Amblard F, Schinazi RF.. (2017) Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector., 138 [PMID:28688280] [10.1016/j.ejmech.2017.06.062] |
| 27. Han X, Zhou C, Jiang M, Wang Y, Wang J, Cheng Z, Wang M, Liu Y, Liang C, Wang J, Wang Z, Weikert R, Lv W, Xie J, Yu X, Zhou X, Luangsay S, Shen HC, Mayweg AV, Javanbakht H, Yang S.. (2018) Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action., 61 (23): [PMID:30286292] [10.1021/acs.jmedchem.8b01245] |
| 28. Unpublished dataset, |
| 29. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard. (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, [10.1101/2020.04.03.023846] |
| 30. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson. (2020) Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2, [10.1101/2020.04.21.054387] |
| 31. Kumamoto H, Imoto S, Amano M, Kuwata-Higashi N, Baba M, Mitsuya H, Odanaka Y, Shimbara Matsubayashi S, Tanaka H, Haraguchi K.. (2018) Synthesis, Anti-HBV, and Anti-HIV Activities of 3'-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines., 9 (12): [PMID:30613328] [10.1021/acsmedchemlett.8b00374] |
| 32. Qiu J, Chen W, Zhang Y, Zhou Q, Chen J, Yang L, Gao J, Gu X, Tang D.. (2019) Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors., 176 [PMID:31091479] [10.1016/j.ejmech.2019.05.014] |
| 33. Wang A, Wu S, Tao Z, Li X, Lv K, Ma C, Li Y, Li L, Liu M.. (2019) Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs., 10 (6): [PMID:31223460] [10.1021/acsmedchemlett.9b00184] |
| 34. Lin X, Shi H, Zhang W, Qiu Z, Zhou Z, Dey F, Zhong S, Qiu H, Xie J, Zhou X, Yang G, Tang G, Shen HC, Zhu W.. (2019) A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles., 62 (22): [PMID:31689116] [10.1021/acs.jmedchem.9b01421] |
| 35. Qiu Z, Lin X, Zhou M, Liu Y, Zhu W, Chen W, Zhang W, Guo L, Liu H, Wu G, Huang M, Jiang M, Xu Z, Zhou Z, Qin N, Ren S, Qiu H, Zhong S, Zhang Y, Zhang Y, Wu X, Shi L, Shen F, Mao Y, Zhou X, Yang W, Wu JZ, Yang G, Mayweg AV, Shen HC, Tang G.. (2016) Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors., 59 (16): [PMID:27458651] [10.1021/acs.jmedchem.6b00879] |
| 36. Wang C, Pei Y, Wang L, Li S, Jiang C, Tan X, Dong Y, Xiang Y, Ma Y, Liu G.. (2020) Discovery of (1H-Pyrazolo[3,4-c]pyridin-5-yl)sulfonamide Analogues as Hepatitis B Virus Capsid Assembly Modulators by Conformation Constraint., 63 (11): [PMID:32421339] [10.1021/acs.jmedchem.0c00292] |
| 37. Lv K, Li W, Wu S, Geng Y, Wang A, Yang L, Huang M, Chowdhury K, Li Y, Liu M.. (2020) Amino acid prodrugs of NVR3-778: Design, synthesis and anti-HBV activity., 30 (9): [PMID:32173194] [10.1016/j.bmcl.2020.127103] |
| 38. Chen W, Liu F, Zhao Q, Ma X, Lu D, Li H, Zeng Y, Tong X, Zeng L, Liu J, Yang L, Zuo J, Hu Y.. (2020) Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors., 63 (15): [PMID:32692159] [10.1021/acs.jmedchem.0c00346] |
| 39. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 40. Luo M,Wu S,Kalkeri R,Ptak RG,Zhou T,Van Mellaert L,Wang C,Dumbre SG,Block T,Groaz E,De Jonghe S,Li Y,Herdewijn P. (2020) Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug., 63 (22.0): [PMID:33191744] [10.1021/acs.jmedchem.0c01381] |
| 41. Gu X,Zhang Y,Zou Y,Li X,Guan M,Zhou Q,Qiu J. (2021) Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents., 29 [PMID:33285406] [10.1016/j.bmc.2020.115892] |
| 42. Amblard F,Boucle S,Bassit L,Chen Z,Sari O,Cox B,Verma K,Ozturk T,Ollinger-Russell O,Schinazi RF. (2021) Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents., 31 [PMID:33421915] [10.1016/j.bmc.2020.115952] |
| 43. Samunuri, Ramakrishnamraju, Toyama, Masaaki, Pallaka, Renuka Sivasankar, Neeladri, Seshubabu, Jha, Ashok Kumar, Baba, Masanori, Bal, Chandralata. (2020) Synthesis and anti-HBV activity of carbocyclic nucleoside hybrids with salient features of entecavir and aristeromycin, 11 (5): [PMID:33479662] [10.1039/d0md00059k] |
| 44. Qiu J,Zhou Q,Zhang Y,Guan M,Li X,Zou Y,Huang X,Zhao Y,Chen W,Gu X. (2020) Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents., 205 [PMID:32791397] [10.1016/j.ejmech.2020.112581] |
| 45. Amblard F, Patel D, Michailidis E, Coats SJ, Kasthuri M, Biteau N, Tber Z, Ehteshami M, Schinazi RF.. (2022) HIV nucleoside reverse transcriptase inhibitors., 240 [PMID:35792384] [10.1016/j.ejmech.2022.114554] |
| 46. Hwang N, Ban H, Wu S, McGuire K, Hernandez E, Chen J, Zhao Q, Suresh M, Blass B, Viswanathan U, Kulp J, Chang J, Clement J, Menne S, Guo JT, Du Y.. (2022) 4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators., 58 [PMID:34979256] [10.1016/j.bmcl.2021.128518] |
| 47. Hu Y, Sun F, Yuan Q, Du J, Hu L, Gu Z, Zhou Q, Du X, He S, Sun Y, Wang Q, Fan L, Wang L, Qin S, Chen S, Li J, Wu W, Mao J, Zhou Y, Zhou Q, Zhang G, Ding CZ.. (2022) Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection., 75 [PMID:36089112] [10.1016/j.bmcl.2022.128977] |
| 48. European Medicines Agency, |
